**Supplementary Table 1.** Questions to be addressed by the systematic literature review, following a Delphi-based approach, and keywords used for the Pubmed search

|  |  |
| --- | --- |
| **Pharmacologic treatment of SLE** | **Pubmed search strings** |
| 1. What is the evidence for the benefits and harms of glucocorticoids in treating SLE? | (SLE [Title] OR DLE[Title] OR "lupus"[Title] OR SCLE[Title] OR CLE[Title]) **AND** (glucocorticoid\* OR steroid\* OR corticosteroid\* OR hydroxychloroquine OR antimalarial\* OR quinacrine OR methotrexate OR leflunomide OR calcineurin OR cyclosporin OR tacrolimus OR voclosporin OR azathioprine OR mycophenolate OR mycophenolic OR cyclophosphamide OR rituximab OR belimumab OR abatacept OR biologic\* OR “intravenous immunoglobulin” OR “plasma exchange” OR plasmapheresis) |
| 1. What is the evidence for the benefits and harms of hydroxychloroquine in treating SLE? |
| 1. What is the evidence for the benefits and harms of immunosuppressive/cytotoxic agents in treating SLE? |
| 1. What is the evidence for the benefits and harms of calcineurin inhibitors in treating SLE? |
| 1. What is the evidence for the benefits and harms of biologics in treating SLE? |
| **Treatment of specific manifestations** | **Points to consider** |
| 1. How should skin involvement in SLE be treated? | ("lupus rash"[Title] OR "malar rash"[Title] OR "skin lupus"[Title] OR "cutaneous lupus"[Title] OR DLE[Title] OR "discoid lupus"[Title] OR SCLE[Title] OR CLE[Title] OR "chilblain lupus"[Title] OR "lupus tumidus"[Title] OR "lupus panniculitis"[Title]) AND ("sun protection" OR "topical" OR retinoid\* OR thalidomide OR lenalidomide OR dapsone) |
| 1. How should renal involvement in SLE be treated? | Identical search as per questions 1 to 5 with additional hand search of retrieved articles |
| 1. How should neuropsychiatric (NP) involvement in SLE be treated? | Identical search as per questions 1 to 5 with additional hand search of retrieved articles |
| 1. Management of antiphospholipid syndrome in SLE | (SLE[Title] OR "lupus"[Title]) AND (anti-b2\* OR anti-beta\* OR anti-β2\* OR anti-cardiolipin\* OR anticardiolipin\* OR "lupus anticoagulant" OR LAC OR aPL) AND (syndrome OR APS OR thrombosis OR thrombotic OR vascular OR pregnan\* OR obstetric\*) AND (management OR therapy OR therapeutic OR treatment OR anticoagul\* OR antiplatelet\* OR anti-platelet\* OR aspirin OR heparin OR warfarin) |
| 1. How should SLE flares be treated? | (SLE[Title] OR "lupus"[Title]) AND (flare\*[Title] OR flaring[Title] OR exacerbat\*[Title] OR relaps\*[Title]) |
| **Monitoring and treatment targets** |  |
| 1. How often and by which means should disease activity and damage be assessed in SLE? |  |
| 1. What are the optimal treatment targets in SLE? | (SLE[Title] OR "lupus"[Title]) AND (treatment OR therapy OR management) AND (target[Title] OR aim[Title] OR response[Title] OR inactive[Title] OR remission[Title/Abstract] OR "low disease activity"[Title/Abstract]) |
| 1. What is the optimal duration of immunosuppressive/biologic treatment in SLE? | (SLE [Title] OR "lupus"[Title]) AND (treatment OR therapy OR management) AND (stop\*[Title/Abstract] OR withdraw\*[Title/Abstract] OR discontin\*[Title/Abstract] OR taper\*[Title/Abstract] OR duration [Title/Abstract]) |
| **Comorbidities and adjunct therapy for SLE** |  |
| 1. How should comorbidities be managed in SLE? | (SLE[Title] OR "lupus"[Title]) AND (comorbid\*[Title] OR infectio\*[Title] OR vaccin\*[Title] OR immuniz\*[Title] OR osteoporo\*[Title] OR bone[Title] OR cardiovascular[Titlle] OR atherosclero\*[Title] OR myocardial[Title] OR angina[Title] OR heart[Title] OR "peripheral arterial"[Title] OR "peripheral vascular"[Title] OR claudication[Title] OR hypertension[Title] OR dyslipidaemia[Title] OR hypercholesterol\*[Title] OR diabetes[Title] OR hyperglycem\*[Title] OR cancer[Title] OR malignan\*[Title] OR fatigue[Title] OR pain[Title]) |